Publications by authors named "Benjamin Derman"

Claim this Profile
T
The role of maintenance therapy and its cessation in patients with multiple myeloma.
Abigail P Sneider, Benjamin A Derman

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series.
Varsha Swamy, Kaitlin Kelly, Jay L Koyner, Benjamin A Derman, Marco Bonilla

Kidney Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?
Benjamin A Derman

Hematology Am Soc Hematol Educ Program· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Tadeusz Kubicki, Benjamin A Derman, Jennifer H Cooperrider, Anna Puła, David Barnidge

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy.
Jennifer H Cooperrider, Benjamin A Derman

Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.
Jennifer H Cooperrider, Diren Arda Karaoglu, Tadeusz Kubicki, Can Rui Jiang, Ella Postich, Benjamin A Derman

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical applications of mass spectrometry in multiple myeloma.
Benjamin A Derman, Andrew J Yee

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Benjamin A Derman, Jennifer Cooperrider, Anna Pula, Heidi Simmons, Tadeusz Kubicki

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Kaitlin Kelly, Jennifer H Cooperrider, Michael R Bishop, Satyajit Kosuri, Andrzej Jakubowiak, Benjamin A Derman

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.
Tony Pan, Erting Tang, Yifei Hu, Nicholas Asby, Mckenzie Schubat, Benjamin Derman

medRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.
Ola Landgren, Noa Biran, Elizabeth K O'Donnell, Joseph Mikhael, Katja C Weisel, Benjamin A Derman

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
Heather T Morgan, Benjamin A Derman, Hong Ma, Shaji K Kumar

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic, Benjamin Derman

J Natl Compr Canc Netw· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.
Gayathri Ravi, Shambavi Richard, Shaji Kumar, Shebli Atrash, Michaela Liedtke, Benjamin Derman

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.
Benjamin Derman, Carlyn Tan, Ian Steinfield, Florence R Wilson, Dee Lin

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
David Barnidge, Dhananjay Sakrikar, Tadeusz Kubicki, Benjamin A Derman, Andrzej J Jakubowiak

J Appl Lab Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Benjamin A Derman

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.
Tyra K Grischke, Jennifer H Cooperrider, Anna Pula, Abigail Sneider, Samuel Yates, Benjamin A Derman

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Bei Wang, Benjamin A Derman, Madina Sukhanova, Daniel Appelbaum, John Cursio

Blood Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline predisposition in multiple myeloma.
Fernanda Martins Rodrigues, Jagoda Jasielec, Melody Perpich, Aelin Kim, Luke Moma, Benjamin Derman

iScience· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
Marcus Marable, Kaitlin Kelly, Jennifer H Cooperrider, Andrzej Jakubowiak, Benjamin A Derman

EJHaem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Access to T-Cell Therapies in Multiple Myeloma.
Benjamin A Derman

Clin Lymphoma Myeloma Leuk· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Benjamin A Derman, Ajay Major, Jennifer Cooperrider, Ken Jiang, Aubrianna Ramsland

Blood Cancer J· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.
Kashyap Padmaraju, Kaitlin Kelly, Andrzej J Jakubowiak, Benjamin A Derman

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Yi Lin, Lugui Qiu, Saad Usmani, Chng Wee Joo, Luciano Costa, Benjamin Derman

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis